Friday, Nov 20, 2026
English News
  • Hyderabad
  • Telangana
  • AP News
  • India
  • World
  • Entertainment
  • Sport
  • Science and Tech
  • Business
  • Rewind
  • ...
    • NRI
    • View Point
    • cartoon
    • My Space
    • Education Today
    • Reviews
    • Property
    • Lifestyle
E-Paper
  • NRI
  • View Point
  • cartoon
  • My Space
  • Reviews
  • Education Today
  • Property
  • Lifestyle
Home | Business | Lupin Gets Usfda Tentative Approval For Generic Prostate Cancer Drug

Lupin gets USFDA tentative approval for generic prostate cancer drug

Lupin Ltd has received tentative approval from the USFDA for its generic enzalutamide tablets used to treat castration-resistant prostate cancer. The approval covers four dosage strengths, including 120 mg and 160 mg variants, offering healthcare providers and patients more dosing options

By PTI
Published Date - 26 June 2026, 02:12 PM
Lupin gets USFDA tentative approval for generic prostate cancer drug
whatsapp facebook twitter telegram

New Delhi: Homegrown pharma major Lupin Ltd on Friday said it has received tentative approval from the US health regulator for its generic version of enzalutamide tablets indicated for the treatment of castration-resistant prostate cancer.

The tentative approval from the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for enzalutamide tablets in strengths of 40 mg, 80 mg, 120 mg and 160 mg, Lupin said in a regulatory filing.


The USFDA has tentatively approved Lupin’s enzalutamide tablets in 40 mg and 80 mg strengths as bioequivalent to the Reference Listed Drug (RLD), Xtandi tablets, of Astellas.

While Xtandi tablets are traditionally available in 40 mg and 80 mg strengths, Lupin’s tentatively approved 120 mg and 160 mg strengths will offer healthcare providers and patients alternative dosing options, the company said.

Join Our Whatsapp Channel
  • Follow Us :
As preferred source
  • Tags
  • enzalutamide tablets
  • Lupin
  • prostate cancer treatment
  • USFDA approval

Related News

  • KIMS Hospital treats 13 patients with advanced Tulsa-Pro technology

    KIMS Hospital treats 13 patients with advanced Tulsa-Pro technology

  • Hyderabad-based Natco Pharma gets FDA approval for marketing Bosentan Tablets in the United States

    Hyderabad-based Natco Pharma gets FDA approval for marketing Bosentan Tablets in the United States

  • Lupin recalls 51,000 bottles of generic antibiotic drug in US

    Lupin recalls 51,000 bottles of generic antibiotic drug in US

  • Nearly 90% of patients don’t use inhalers correctly

    Nearly 90% of patients don’t use inhalers correctly

Latest News

  • Telangana High Court asks Teenmar Mallanna to approach SC on special courts’ jurisdiction

    18 minutes ago
  • Ponnam seeks merger of Husnabad mandals with Karimnagar

    34 minutes ago
  • Revanth left disappointed Siddipet people as he fails to grant any special funds

    52 minutes ago
  • NITW, KITS Warangal sign renewed MoU to strengthen academic, research collaboration

    1 hour ago
  • Revanth Reddy’s Siddipet meeting draws poor turnout

    2 hours ago
  • Revanth Reddy hits back at Congress critics, threatens to send them to Erragadda

    2 hours ago
  • Joshua strikes late as RSB Hyderabad beat Bengaluru 2-1

    2 hours ago
  • How Financial Behavior Affects Your Eligibility for a Personal Loan

    2 hours ago

company

  • Home
  • About Us
  • Contact Us
  • Privacy Policy

business

  • Subscribe

telangana today

  • Telangana
  • Hyderabad
  • Latest News
  • Entertainment
  • World
  • Andhra Pradesh
  • Science & Tech
  • Sport

follow us

  • Telangana Today Telangana Today
Telangana Today Telangana Today

© Copyrights 2024 TELANGANA PUBLICATIONS PVT. LTD. All rights reserved. Powered by Veegam

Telangana Today App